黄柏苷
黄柏苷 性质
| 沸点 | 861.5±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.504±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。 |
| 形态 | 粉末 |
| 酸度系数(pKa) | 7.15±0.60(Predicted) |
| 颜色 | 浅黄至黄色 |
| 生物来源 | plant |
| 水溶解性 | water: slightly soluble |
| 主要应用 | metabolomics vitamins, nutraceuticals, and natural products |
| InChIKey | GRDZTDZJQRPNCN-YIANMRPHSA-N |
| SMILES | O1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)Oc2c(c3c(c(c2)O)C(=O)[C@@H]([C@H](O3)c4ccc(cc4)O)O)CC=C(C)C |
黄柏苷 用途与合成方法
Phellamurin (0-10 μg/mL; 48 hours; U2OS and Saos-2 cells) treatment leads to a repression of cell viability in U2OS and Saos-2 cells in a dose-dependent manner.
Phellamurin (0-10 μg/mL; 48 hours; U2OS and Saos-2 cells) treatment concentration-dependently promots the apoptosis of U2OS and Saos-2 cells.
Phellamurin (0-10 μg/mL; 48 hours; U2OS and Saos-2 cells) treatment declines the ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR in U2OS and Saos-2 cells.
Cell Viability Assay
| Cell Line: | U2OS and Saos-2 cells |
| Concentration: | 0 μg/mL, 2.5 μg/mL, 5 μg/mL, and 10 μg/mL |
| Incubation Time: | 48 hours |
| Result: | Suppressed the viability of U2OS and Saos-2 cells in a concentration-dependent manner. |
Apoptosis Analysis
| Cell Line: | U2OS and Saos-2 cells |
| Concentration: | 0 μg/mL, 2.5 μg/mL, 5 μg/mL, and 10 μg/mL |
| Incubation Time: | 48 hours |
| Result: | Induced apoptosis of U2OS and Saos-2 cells in a concentration-dependent manner. |
Western Blot Analysis
| Cell Line: | U2OS and Saos-2 cells |
| Concentration: | 0 μg/mL and 10 μg/mL |
| Incubation Time: | 48 hours |
| Result: | Repressed the PI3K/AKT/mTOR pathway in U2OS and Saos-2 cells. |
Phellamurin (50 mg/kg/day; intraperitoneal injection; daily; for 21 days; female BALB/c nude mice) treatment represses osteosarcoma tumor growth in vivo. The ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR are decreased in xenograft in Phellamurin-treated mice.
| Animal Model: | Athymic female BALB/c nude mice (6 weeks old ) injected with U2OS cells |
| Dosage: | 50 mg/kg/day |
| Administration: | Intraperitoneal injection; daily; for 21 days |
| Result: | Repressed osteosarcoma tumor growth in vivo. |
